Long-term safety of oral orforglipron in Japanese participants with type 2 diabetes (ACHIEVE-J): a multicentre, randomised, open-label, parallel-group phase 3 trial

The Lancet Diabetes & Endocrinology · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles